Thursday, October 8, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 19, 2026

The SoFi CEO Just Bought 70,000 Shares With His Own Money. Here Are Four More Under $30 Worth a Closer Look

View original at finance.yahoo.com
“lifted cash to $18.2B at year-end 2025 from $3.3B a year earlier.”
Verbatim excerpt from the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Equity markets are trading at elevated multiples in May 2026

    60% confidence

  • AT&T legacy wireline revenue declined more than 20% in 2026

    60% confidence

  • Analyst consensus target price for Pfizer is $29.19

    60% confidence

  • Analyst target price for SoFi Technologies is $21.10

    60% confidence

  • Pfizer's non-COVID portfolio achieved 9% operational revenue growth

    60% confidence

  • Analyst target price for AT&T is $30.37

    60% confidence

  • AT&T Q1 2026 adjusted EPS grew 11.8% year-over-year to $0.57

    60% confidence

  • SoFi Q1 2026 net income increased 134% year-over-year to $166.7 million

    60% confidence

  • AT&T grew its cash position from $3.3 billion at year-end 2024 to $18.2 billion at year-end 2025

    60% confidence

  • SoFi Q1 2026 loan originations reached a record $12.18 billion, up 68% year-over-year

    60% confidence

  • AT&T's converged connectivity and growing free cash flow makes the dividend durable

    60% confidence

  • Pfizer faces a $1.5 billion revenue headwind in 2026 from loss of drug exclusivity and Most Favored Nation drug pricing pressure

    60% confidence

Data points we hold from this source

AT&T Inc. · debt173.99 USD
AT&T Inc. · analyst target price30.37 USD
AT&T Inc. · forward pe11 multiple
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,362 source documents archived
Query this data → isubstrate.com
The SoFi CEO Just Bought 70,000 Shares With His Own Money. Here Are Four More Under $30 Worth a Closer Look — Source | Via News | ViaNews Market